Ritholtz Wealth Management raised its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 145.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,392 shares of the company’s stock after acquiring an additional 12,100 shares during the period. Ritholtz Wealth Management’s holdings in Zoetis were worth $1,424,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Jacobi Capital Management LLC boosted its holdings in Zoetis by 6.0% in the third quarter. Jacobi Capital Management LLC now owns 15,388 shares of the company’s stock valued at $1,075,000 after purchasing an additional 875 shares during the last quarter. Jefferies Financial Group Inc. grew its position in Zoetis by 35.0% during the 3rd quarter. Jefferies Financial Group Inc. now owns 25,000 shares of the company’s stock worth $1,746,000 after purchasing an additional 6,475 shares during the period. First Command Advisory Services Inc. raised its stake in shares of Zoetis by 3,881.8% during the 3rd quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock valued at $31,000 after buying an additional 427 shares during the last quarter. Illinois Municipal Retirement Fund raised its stake in shares of Zoetis by 1.8% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 12,148 shares of the company’s stock valued at $848,000 after buying an additional 218 shares during the last quarter. Finally, Inspire Trust Co. N.A. purchased a new position in shares of Zoetis during the 3rd quarter valued at about $3,841,000. 92.80% of the stock is owned by hedge funds and other institutional investors.
Zoetis Stock Down 0.2%
ZTS stock opened at $83.65 on Monday. The firm has a market cap of $33.99 billion, a PE ratio of 14.23, a P/E/G ratio of 1.21 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The firm’s fifty day moving average is $76.28 and its 200 day moving average is $91.56. Zoetis Inc. has a one year low of $68.77 and a one year high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.70 earnings per share. On average, research analysts forecast that Zoetis Inc. will post 6.29 EPS for the current year.
Zoetis Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.5%. Zoetis’s dividend payout ratio (DPR) is 36.05%.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ZTS. Morgan Stanley lowered their target price on Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a research note on Thursday, October 29th. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research report on Tuesday, August 25th. TD Cowen decreased their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Finally, Citigroup decreased their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Eight investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $101.25.
Read Our Latest Research Report on Zoetis
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Articles
- Five stocks we like better than Zoetis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
